Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Tg Therapeutics Inc.
Sponsor

Tg Therapeutics Inc.

United States 3020 Carrington Mill Boulevard Suite 475, 27560-5435, United States

About the sponsor

Tg Therapeutics Inc. focuses on relapsing multiple sclerosis and related relapsing disease presentations, with clinical activity centered on long-term safety, efficacy, and radiological outcomes in people living with active disease.

  • Relapsing forms of multiple sclerosis
  • Relapsing multiple sclerosis
  • Radiological disease activity

The sponsor’s work in this area includes adult and pediatric populations, reflecting interest across different stages of multiple sclerosis care.

About Specializations

Tg Therapeutics Inc. runs clinical trials in conditions such as Relapsing multiple sclerosis, Myasthenia gravis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

6 clinical trials

Relapsing multiple sclerosis

Recruiting

A study to evaluate the safety and how the body uses ublituximab injections in patients with multiple sclerosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ublituximab
  • Sponsor:Tg Therapeutics Inc.

Relapsing multiple sclerosis

Recruiting

Study on the Effectiveness of Ublituximab and Drug Combination for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cetirizine
  • Sponsor:Tg Therapeutics Inc.

Relapsing multiple sclerosis

Recruiting

Study of ublituximab compared to fingolimod for children and teenagers aged 10 to 17 years with relapsing multiple sclerosis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Fingolimod
  • Sponsor:Tg Therapeutics Inc.

Relapsing multiple sclerosis

Not recruiting

Study on Ublituximab for Patients with Relapsing Multiple Sclerosis

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Ublituximab
  • Sponsor:Tg Therapeutics Inc.

Relapsing multiple sclerosis

Not recruiting

Study comparing subcutaneous versus intravenous ublituximab in patients with relapsing multiple sclerosis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Ublituximab
  • Sponsor:Tg Therapeutics Inc.

Myasthenia gravis+1

Not recruiting

Study on Ublituximab and Drug Combination for Patients with Myasthenia Gravis or Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cetirizine
  • Sponsor:Tg Therapeutics Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.